Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage company based in Seattle, Washington, that specializes in immune-driven medicine by leveraging the adaptive immune system for disease diagnosis and treatment. The company's flagship clinical diagnostic product, clonoSEQ, is FDA-authorized for detecting and monitoring minimal residual disease in patients with specific blood cancers, including multiple myeloma and certain types of leukemia. Furthermore, Adaptive Biotechnologies offers the immunoSEQ research service and kit, aiding in the discovery of prognostic and diagnostic signals. The company has established strategic collaborations with notable partners such as Genentech for developing T cell therapies, Microsoft to create diagnostic tests from a single blood sample, and Amgen to explore therapeutic options for COVID-19. In addition to its diagnostic services, Adaptive Biotechnologies is focused on developing a pipeline of products aimed at addressing cancer, autoimmune conditions, and infectious diseases. Founded in 2009, the company has grown to play a significant role in the life sciences research and clinical diagnostics sectors.